<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8809320</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1600</journal-id>
<journal-id journal-id-type="nlm-ta">Neuron</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuron</journal-id>
<journal-title-group>
<journal-title>Neuron</journal-title>
</journal-title-group>
<issn pub-type="ppub">0896-6273</issn>
<issn pub-type="epub">1097-4199</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26898776</article-id>
<article-id pub-id-type="pmc">4783174</article-id>
<article-id pub-id-type="doi">10.1016/j.neuron.2016.01.025</article-id>
<article-id pub-id-type="manuscript">NIHMS761735</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Developmental inhibition of Gsk3 rescues behavioral and neurophysiological deficits in a mouse model of schizophrenia predisposition</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tamura</surname>
<given-names>Makoto</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mukai</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gordon</surname>
<given-names>Joshua A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gogos</surname>
<given-names>Joseph A.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032</aff>
<aff id="A2"><label>2</label>Department of Physiology and Cellular Biophysics 1150 St. Nicholas Ave, New York, NY 10032</aff>
<aff id="A3"><label>3</label>Department of Neuroscience, Columbia University, 1051 Riverside Drive, New York, NY 10032</aff>
<aff id="A4"><label>4</label>Pharmacology Research Laboratories I, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033 Japan</aff>
<aff id="A5"><label>5</label>Division of Integrative Neuroscience, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032</aff>
<author-notes>
<corresp id="FN1">For correspondence: Joshua A. Gordon, <email>jg343@cumc.columbia.edu</email>. Joseph A. Gogos, <email>jag90@cumc.columbia.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>2</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>2</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>02</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>89</volume>
<issue>5</issue>
<fpage>1100</fpage>
<lpage>1109</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuron.2016.01.025-->
<abstract>
<title>SUMMARY</title>
<p id="P3">While the genetic basis of schizophrenia is increasingly well-characterized, novel treatments will require establishing mechanistic relationships between specific risk genes and core phenotypes. Rare, highly-penetrant risk genes such as the 22q11.2 microdeletion are promising in this regard. <italic>Df(16)A<sup>+/−</sup></italic> mice, which carry a homologous microdeletion, have deficits in hippocampal-prefrontal connectivity that correlate with deficits in spatial working memory. These mice also have deficits in axonal development that are accompanied by dysregulated Gsk3β signaling and can be rescued by Gsk3 antagonists. Here, we show that developmental inhibition of Gsk3 rescues deficits in hippocampal-prefrontal connectivity, task-related neural activity, and spatial working memory behavior in <italic>Df(16)A<sup>+/−</sup></italic> mice. Taken together, these results provide mechanistic insight into how the microdeletion results in cognitive deficits, and suggest possible targets for novel therapies.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>